We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Pentoxifylline in the Treatment of Experimental Peritonitis in Rats

Georges E. Chalkiadakis, MD; Alkiviadis Kostakis, MD; Panayotis E. Karayannacos, MD; Maria E. Chalkiadakis, MSc; Stella Sgouromali, MD; Helen Giamarellou, MD; Gregory D. Skalkeas, MD
Arch Surg. 1985;120(10):1141-1144. doi:10.1001/archsurg.1985.01390340039007.
Text Size: A A A
Published online


• The objective of this study was to determine the effect of pentoxifylline on the clinical and pathologic course of experimentally induced peritonitis in rats. This drug is a methyxanthine derivative that has vasodilating properties and may decrease platelet aggregation. Peritonitis was induced in 40 Wistar rats by creating a closed ileal loop 4 cm long 5 cm from the ileocecal valve. The animals were divided into two groups of 20 animals each. The first group served as controls, while each animal of the second group received 17 mg/kg/day of pentoxifylline intramuscularly from the day of operation until 30 days postoperatively. The survival rate was significantly Increased in the group receiving pentoxifylline and adhesion or abscess formation was considerably reduced. We concluded that the administration of pentoxifylline prolongs significantly the survival of animals with experimental peritonitis and reduces the development of adhesions and abscesses in the peritoneal cavity. This beneficial effect may be attributed to decreased fibrinogen deposits and increased fibrinolytic activity within the peritoneal cavity, thus rendering the bacteria more susceptible to cellular and noncellular clearing mechanisms.

(Arch Surg 1985;120:1141-1144)


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?





Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.